Demographic and clinical characteristics of PsA patients with peripheral and axial disease. Values are mean ± SD or median (interquartile range) unless otherwise indicated. There was no significant difference in demographic and clinical characteristics between patients with peripheral and axial disease, except in mental component summary score of the SF-36.
| Characteristic | Whole Group, n = 125 | Peripheral Disease, n = 101 | Axial Disease, n = 24 |
|---|---|---|---|
| Age, yrs | 47 ± 12 | 48 ± 13 | 46 ± 10 |
| Male, no. (%) | 65 (52) | 51 (51) | 14 (58) |
| Married, no. (%) | 84 (67) | 68 (67) | 16 (67) |
| Education, yrs | 9 ± 4 | 8.8 ± 4.0 | 9.1 ± 3.0 |
| Age at PsA diagnosis, yrs | 40 ± 12 | 41 ± 12 | 36 ± 12 |
| Age at psoriasis diagnosis, yrs | 36 ± 14 | 30 ± 14 | 34 ± 13 |
| PsA disease duration, yrs | 6.9 (2.0–12.4) | 6.4 (2.1–11.5) | 10 (2.0–17.3) |
| PASI score | 2.1 (0.9–7.4) | 2.5 (0.9–7.3) | 1.8 (0.9–10.3) |
| Physician global (VAS 0–10) | 2.0 (0–3.0) | 2.0 (0–3.0) | 2.0 (1.0–4.0) |
| Pain (VAS 0–10) | 4.8 ± 2.6 | 4.7 ± 2.5 | 5.0 ± 2.9 |
| Patient global (VAS 0–10) | 4.6 ± 2.3 | 4.4 ± 2.3 | 5.2 ± 2.2 |
| ESR, mm/h | 30.2 ± 26.0 | 38.0 ± 35.6 | 31.7 ± 28.1 |
| CRP, mg/l | 10.7 ± 15.2 | 14.1 ± 19.3 | 11.4 ± 16.0 |
| No. of damaged joints | 1 (0–4) | 1 (0–4) | 2 (0–5) |
| DAS28 | 3.8 ± 1.5 | 3.8 ± 1.5 | 3.8 ± 1.6 |
| HAQ (0–3) | 0.5 (0.1–1.0) | 0.4 (0–0.9) | 1.0 (0.1–1.3) |
| PCS | 40 ± 9 | 41 ± 9 | 37 ± 10 |
| MCS | 43 ± 11 | 44 ± 12 | 38 ± 10† |
↵† p < 0.01, comparison between patients with peripheral and axial disease. PASI: Psoriasis Area and Severity Index; VAS: visual analog scale; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; DAS28: Disease Activity Score in 28 joints; HAQ: Health Assessment Questionnaire; PCS: physical component summary score of the Short-Form 36; MCS: mental component summary score of the Short-Form 36.